Sign in
Taking people in United StatesNo phase

Mouth device for adults with severe obstructive sleep apnea

Tests the EVO Sleep and Snore Device in adults with severe obstructive sleep apnea.

Key facts

Who runs it
ProSomnus Sleep Technologies
Where
Dallas and New York, United StatesSee the 2 sites
Trial code
Registry title
Severe Label Expansion for EVO Products Trial
Status
Recruiting
People taking part
49 people, planned
Started
1 Aug 2025
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • EVO Sleep and Snore Device
Record updated
17 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with severe obstructive sleep apnea (breathing stops often during sleep) to test the EVO Sleep and Snore Device, a mouth device that moves the lower jaw forward.

Age
18 to 80 years
Sex
All sexes
Disease stage
Uncomplicated severe obstructive sleep apnea (AHI > 30 h-1). BMI < 35 kg/m2. Mean night-time oxygen level (SpO2) > 87%. Jaw must move well and teeth must be in good enough condition.
Earlier treatment
Cannot have used CPAP or an oral appliance in the two weeks before the baseline sleep study. Cannot have had an oral appliance that worked in the past two years. Cannot have had surgery to change airway anatomy for sleep apnea.

Main reasons for not taking part

  • Heart or lung disease, stroke, nerve-muscle conditions or long-term opiate use that raise the risk of other breathing problems in sleep
  • More than 25% central sleep apnea, or sleep apnea that depends on body position
  • Hypoglossal nerve stimulator, pacemaker or other life-supporting device
  • Loose teeth, advanced gum disease, jaw joint disorder, or trouble breathing through the nose
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18-80 years (inclusive)
  • Diagnosed with uncomplicated severe OSA (AHI > 30 h-1); where uncomplicated is defined by the absence of:; Conditions that place the patient at increased risk of non-obstructive sleep-disordered breathing (e.g., central sleep apnea, hypoventilation, and sleep-related hypoxemia [e.g., resulting from severe chronic obstructive, interstitial lung disease, or pulmonary hypertension]). Examples of such conditions include significant cardiopulmonary disease (congestive heart failure, recurrent atrial fibrillation, coronary artery disease, resistant hypertension), potential respiratory muscle weakness due to neuromuscular conditions, history of stroke, and chronic opiate medication use; Concern for significant non-respiratory sleep disorder(s) that require evaluation (e.g., disorders of central hypersomnolence, parasomnias, sleep-related movement disorders) or interfere with accuracy of HSAT (e.g., severe insomnia); Environmental or personal factors that preclude the adequate acquisition and interpretation of data from HSAT
  • Body mass index (BMI) < 35 kg/m2
  • Absence of severe oxyhemoglobin desaturation during sleep, indicated by mean nocturnal SpO2 > 87%
  • Adequate mandibular range of motion
  • Adequate dentition

Who cannot take part

  • Use of CPAP or OAT within the two weeks prior to the baseline sleep study
  • History of OAT that has been confirmed to provide effective therapy within the two years prior to the baseline sleep study
  • Anticipated change in medical therapy during the study protocol that could alter OSA severity (e.g., weight loss surgery, weight loss drug, UPPP, MMA, tongue/hyoid suspension, etc.)
  • History of surgery intended to alter anatomy for the correction of OSA; E.g., uvulopalatopharyngoplasty (UPPP), maxillomandibular advancement (MMA), tongue/hyoid suspension, slow maxillary expansion; History of surgery intended to restore normal anatomy, such as tonsillectomy, adenoidectomy, septoplasty, or polypectomy, is permitted
  • Loose teeth or advanced periodontal disease
  • History of temporomandibular joint disorder
  • Resistant hypertension, defined as inadequately controlled blood pressure despite therapy with; ≥ 3 oral hypertensive agents
  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Inability to breathe through the nose comfortably
  • Presence of > 25% CSA
  • Presence of positional OSA per Amsterdam Positional OSA Classification I definition
  • Presence of hypoglossal nerve stimulation device (active or inactive)
  • Use of pacemaker or other life-supporting device
  • Participation in other studies that could interfere with the study protocol
  • Pregnancy or lactation
  • In the opinion of the investigator, unsuitable for inclusion in the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • Star Sleep and WellnessDallas, United StatesContact: Xzavier Ozuna, MBATaking people
  • Mount Sinai Integrative Sleep CenterNew York, United StatesContact: Research ManagerTaking people

About the trial

What the trial wants to find out

Title: Severe Label Expansion for EVO Positioner (SLEEP) Study Description: Single-arm study to determine the safety and effectiveness of treating severe obstructive sleep apnea using the EVO Sleep and Snore Device (ProSomnus Sleep Technologies, Pleasanton, CA).

Read full original descriptionShow less

Objectives: To determine the safety and effectiveness of the EVO Sleep and Snore Device in individuals with severe obstructive sleep apnea.

Endpoints: The primary effectiveness endpoint is the Sher criteria defined as a reduction of Apnea-Hypopnea Index (AHI) of at least 50% from the baseline value and a post-treatment AHI of less than 20 events/hour at 6 months following initiation of Oral Appliance Therapy (OAT) titration. AHI will be collected using HSAT at baseline and 6 months. The primary safety objective is to evaluate safety by summarizing all reported device and/or procedure related adverse events from the time the EVO device is introduced through 6 months. Study Population: A maximum of 49 individuals over the age of 18 years with severe obstructive sleep apnea will be enrolled.

Description of Sites/Facilities Enrolling Participants: The study will be conducted at up to four sites, up to two of which could be located outside of the US. Description of Study Device: The study device is the EVO Sleep and Snore Device (ProSomnus Sleep Technologies, Pleasanton, CA). The device is a mandibular repositioning device used to treat obstructive sleep apnea. The device is currently cleared for the treatment of mild and moderate OSA.

Study Duration: The time from when the study opens to enrollment until completion of data analyses is estimated to be 15 months.

The group in the trial

  • EVO Sleep and Snore DeviceTreatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Severe Label Expansion for EVO Products Trial
Plain-language title
Mouth device for adults with severe obstructive sleep apneaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07090395, who can take part
Record updated
17 March 2026